{"id":{"repo_id":"mit","oai_identifier":"oai:dspace.mit.edu:1721.1/35131"},"canonical_url":"https://search.dev.ndltd.org/etd/mit/oai:dspace.mit.edu:1721.1/35131","repository":{"repo_id":"mit","name":"MIT","base_url":"https://dspace.mit.edu/oai/request"},"display":{"title":"Academia versus industry as a wellspring of new ideas in drug discovery : the case of oncology","abstract":"The United States population is aging, and the need for novel approaches to treat and manage disease continues to grow. Among the diseases that will impact this population, cancer remains a therapeutic area with significant unmet need. Pharmaceutical and biotechnology industries must continue to meet revenue and income growth expectations and will become increasingly dependent on novel drugs in their pipelines. In order for the pharmaceutical and biotechnology industries to meet the demands of both patients and shareholders, productivity in the research and development process will need to improve significantly. In order to understand how best to improve the drug discovery and development process, it is important to identify potential sources of innovation throughout the process. Among these, an important consideration is to understand the paths that molecules take through the discovery and development process.","abstract_html":"The United States population is aging, and the need for novel approaches to treat and manage disease continues to grow. Among the diseases that will impact this population, cancer remains a therapeutic area with significant unmet need. Pharmaceutical and biotechnology industries must continue to meet revenue and income growth expectations and will become increasingly dependent on novel drugs in their pipelines. In order for the pharmaceutical and biotechnology industries to meet the demands of both patients and shareholders, productivity in the research and development process will need to improve significantly. In order to understand how best to improve the drug discovery and development process, it is important to identify potential sources of innovation throughout the process. Among these, an important consideration is to understand the paths that molecules take through the discovery and development process.","abstract_has_math":false,"creators":["Conde, Jorge Cesar"],"institution":"Massachusetts Institute of Technology","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Harvard University--MIT Division of Health Sciences and Technology.","school":null,"contributors":[],"advisors":["Fiona Murray."],"committee_chairs":[],"committee_members":[],"year":2006,"date_issued":"2006","date_published":"2006","updated_at":"2026-07-22T22:21:20Z","subjects":["Harvard University--MIT Division of Health Sciences and Technology."],"languages":["eng"],"rights":["M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission."],"rights_urls":["http://dspace.mit.edu/handle/1721.1/7582"],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/1721.1/35131","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Fiona Murray."]},{"key":"dc:contributor.department","label":"Department","values":["Harvard University--MIT Division of Health Sciences and Technology."]},{"key":"dc:contributor.other","label":"Dc Contributor Other","values":["Harvard University--MIT Division of Health Sciences and Technology."]},{"key":"dc:creator","label":"Author","values":["Conde, Jorge Cesar"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2006-12-18T20:45:27Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2006-12-18T20:45:27Z"]},{"key":"dc:date.issued","label":"Date","values":["2006"]},{"key":"dc:publisher","label":"Institution","values":["Massachusetts Institute of Technology"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Harvard University--MIT Division of Health Sciences and Technology."]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission."]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://dspace.mit.edu/handle/1721.1/7582"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/1721.1/35131"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2006.","Includes bibliographical references (leaves 63-64)."]},{"key":"dc:description.abstract","label":"Abstract","values":["The United States population is aging, and the need for novel approaches to treat and manage disease continues to grow. Among the diseases that will impact this population, cancer remains a therapeutic area with significant unmet need. Pharmaceutical and biotechnology industries must continue to meet revenue and income growth expectations and will become increasingly dependent on novel drugs in their pipelines. In order for the pharmaceutical and biotechnology industries to meet the demands of both patients and shareholders, productivity in the research and development process will need to improve significantly. In order to understand how best to improve the drug discovery and development process, it is important to identify potential sources of innovation throughout the process. Among these, an important consideration is to understand the paths that molecules take through the discovery and development process.","(cont.) This thesis used the marketplace of oncology drugs in development to test the hypothesis that novel molecules largely originate in academia, are developed by biotechnology companies and ultimately are licensed to pharmaceutical companies for commercialization. This thesis analyzed a database of 364 unique oncology small molecules and biologics entering Phase I clinical development between 1991 and 2002."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["S.M."]},{"key":"dc:format.mimetype","label":"Dc Format Mimetype","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Academia versus industry as a wellspring of new ideas in drug discovery : the case of oncology"]}]}],"canonical_facts":{"dc:contributor.advisor":["Fiona Murray."],"dc:contributor.department":["Harvard University--MIT Division of Health Sciences and Technology."],"dc:contributor.other":["Harvard University--MIT Division of Health Sciences and Technology."],"dc:creator":["Conde, Jorge Cesar"],"dc:date.accessioned":["2006-12-18T20:45:27Z"],"dc:date.available":["2006-12-18T20:45:27Z"],"dc:date.issued":["2006"],"dc:description":["Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2006.","Includes bibliographical references (leaves 63-64)."],"dc:description.abstract":["The United States population is aging, and the need for novel approaches to treat and manage disease continues to grow. Among the diseases that will impact this population, cancer remains a therapeutic area with significant unmet need. Pharmaceutical and biotechnology industries must continue to meet revenue and income growth expectations and will become increasingly dependent on novel drugs in their pipelines. In order for the pharmaceutical and biotechnology industries to meet the demands of both patients and shareholders, productivity in the research and development process will need to improve significantly. In order to understand how best to improve the drug discovery and development process, it is important to identify potential sources of innovation throughout the process. Among these, an important consideration is to understand the paths that molecules take through the discovery and development process.","(cont.) This thesis used the marketplace of oncology drugs in development to test the hypothesis that novel molecules largely originate in academia, are developed by biotechnology companies and ultimately are licensed to pharmaceutical companies for commercialization. This thesis analyzed a database of 364 unique oncology small molecules and biologics entering Phase I clinical development between 1991 and 2002."],"dc:description.degree":["S.M."],"dc:format.mimetype":["application/pdf"],"dc:identifier.uri":["http://hdl.handle.net/1721.1/35131"],"dc:language.iso":["eng"],"dc:publisher":["Massachusetts Institute of Technology"],"dc:rights":["M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission."],"dc:rights.uri":["http://dspace.mit.edu/handle/1721.1/7582"],"dc:subject":["Harvard University--MIT Division of Health Sciences and Technology."],"dc:title":["Academia versus industry as a wellspring of new ideas in drug discovery : the case of oncology"],"dc:type":["Thesis"]},"updated_at":"2026-07-22T22:21:20Z"}